Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia
NCT03764683 · Massachusetts General Hospital · PHASE4 · withdrawn · last registry update 2021-02-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated due to COVID-19.” | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HCRTR2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-02-07Results posted on the registry: Janssen Research & Development, LLC, Placebo + JNJ-42847922 (NCT03227224)
- 2021-10-29Results posted on the registry: Brigham and Women's Hospital, suvorexant + placebo (NCT03034018)
- 2021-07-02Results posted on the registry: University of California, San Francisco, suvorexant + placebo (NCT02593682)
- 2021-06-16Also stopped (terminated): Henry Ford Health System, suvorexant + placebo (NCT02684136)
- 2021-04-28Results posted on the registry: Henry Ford Health System, suvorexant + placebo (NCT02684136)
- 2021-04-12Results posted on the registry: Eisai Inc., LEM 5 mg + LEM 10 mg (NCT04009577)
- 2020-10-01Phase 3 first posted: Merck Sharp & Dohme LLC, Suvorexant + Placebo (NCT04571944)
- 2020-09-16Phase 3 first posted: Eisai Co., Ltd., Lemborexant + Placebo (NCT04549168)
- 2020-08-31Phase 3 first posted: Janssen Research & Development, LLC, Seltorexant + Placebo (NCT04533529)
- 2020-08-31Phase 3 first posted: Janssen Research & Development, LLC, Seltorexant + Placebo (NCT04532749)
- 2020-08-14Phase 3 first posted: Janssen Research & Development, LLC, Seltorexant + Matching placebo to Seltorexant (NCT04513912)
- 2020-06-16Results posted on the registry: VA Palo Alto Health Care System, Suvorexant + Placebo (NCT02491788)
- 2020-04-24Results posted on the registry: Idorsia Pharmaceuticals Ltd., ACT-541468 + Placebo (NCT02841709)
- 2020-04-02Results posted on the registry: Idorsia Pharmaceuticals Ltd., ACT-541468 5 mg + ACT-541468 10 mg (NCT02839200)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision